Phase III study of Epidiolex in Lennox-Gastaut Syndrome published in NEJM.- GW Pharma.

The second of two phase III studies showing that Epidiolex (cannabinoid) from GW Pharma, cut seizures in patients with the rare childhood epilepsy Lennox-Gastaut Syndrome has been published in the New England Journal of Medicine. The trial is the first dose-ranging study to compare cannabidiol to placebo as add-on therapy in Lennox-Gastaut Syndrome and it showed that both doses of Epidiolex significantly reduced drop seizure frequency in patients with poor seizure control despite the use of multiple anti-epileptic drugs. The researchers found that during the 14-week treatment period median reductions in monthly drop seizures were 37.2 percent (10 mg/kg/day dose) and 41.9 percent (20 mg/kg/day), compared with a 17.2 percent reduction for placebo.